KRYS
Krystal Biotech, Inc. · Healthcare · Biotechnology
动量输入（同类管理人）：
持有人广度 +9.1% ·
股份流向 +1.0% ·
净新建仓位 +8.3%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 6.57K | $2.18M | n/a | n/a |
| Q2 2026 | 109 | +2 | 18.97M | $7.05B | +12 | −9 |
| Q1 2026 | 109 | 0 | 17.81M | $4.60B | +7 | −8 |
| Q4 2025 | 109 | +2 | 19.84M | $4.89B | +3 | n/a |
| Q3 2025 | 18 | +1 | 16.09M | $2.84B | +2 | −2 |
| Q2 2025 | 15 | -1 | 14.75M | $2.03B | n/a | −1 |
| Q1 2025 | 13 | +1 | 3.64M | $657.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 3.56M | $557.49M | +1 | n/a |
| Q3 2024 | 10 | +2 | 2.25M | $408.78M | +2 | n/a |
| Q2 2024 | 8 | n/a | 2.10M | $386.05M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (被动) | 1.28M | n/a | $200.36M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Capital World Investors ✦ | 879.20K | 0.0% | $137.74M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 591.60K | 0.0% | $92.70M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | T. Rowe Price ✦ | 509.46K | +16.2% | $79.81M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (被动) | 219.53K | -10.1% | $34.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 18.96K | -60.2% | $2.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 11.70K | -7.7% | $1.83M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 8 | Citadel Advisors ✦ | 11.02K | +11374.0% | $1.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 10.90K | -24.3% | $1.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 10.33K | 新增 | $1.62M | 0.0% | New | 1 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 9.34K | +11.8% | $1.46M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 12 | D. E. Shaw & Co. ✦ | 7.43K | -20.5% | $1.16M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $1.62M | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 364 持有人, 28.19M 股份, $7.07B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer, Director, 10% owner · 399 股 · $146,256
Officer, Director, 10% owner · 3.96K 股 · $1.42M
Officer, Director, 10% owner · 3.18K 股 · $1.14M
Officer, Director, 10% owner · 3.39K 股 · $1.22M
Officer, Director, 10% owner · 2.32K 股 · $836,281
Officer, Director, 10% owner · 1.24K 股 · $449,120
Officer, Director, 10% owner · 1.99K 股 · $722,404
Officer, Director, 10% owner · 565 股 · $205,287
Officer, Director, 10% owner · 1.33K 股 · $484,390
Officer, Director, 10% owner · 826 股 · $301,832
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论